



Chris Beecher

NextGen Metabolomics, USA

Metabolomics: Successes and bottlenecks

Metabolomics has the potential to both find biomarkers and to unravel complex biological processes. The discovery of Sarcosine as a biomarker for prostate cancer aggressivity, and subsequent exploration of some of its biology will be used to highlight this side of metabolomics and will also serve to underscore the bottlenecks and pitfalls to current metabolomic techniques. The IROA protocol will be examined as a way to overcome some of these bottlenecks.

Biography

Chris Beecher was a member of the Department of Pathology, University of Michigan School of Medicine until 2011 when he founded NextGen Metabolomics. He was also one of the founders of Metabolon, and Metabolic Analyses. His Ph.D. was granted in 1985 in Pharmaceutical Sciences specializing in Natural Products drug discovery. He has more than 25 years of experience in metabolomics and drug discovery and development, has published over 80 peer-reviewed papers, and is listed as the inventor of 8 patents in metabolomics.

chris@nextgenmetabolomics.com